October 13, 2025

First Alzheimer's Test for Primary Care

Roche’s FDA-cleared Elecsys pTau181 blood test helps physicians rule out Alzheimer’s pathology early and streamline diagnosis.

Conexiant

October 03, 2025

From Agent Orange to PCBs: Lessons for Care

Air Force reviews cancer risk in missile crews; early analyses show no excess mortality, but exposures to PCBs and benzene prompt vigilance and targeted histories.

KFF Health News

October 01, 2025

How Safe Are FDA-Cleared AI Tools?

“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."

Conexiant

September 26, 2025

Old Medicine, New Hope for Speech?

Leucovorin, a folic acid–derived drug, is under study for speech benefits in children with autism.

KFF Health News

September 23, 2025

Autism Briefing Without CDC Input?

Debate over acetaminophen use in pregnancy and vaccine safety highlights the importance of evidence-based guidance for autism risk counseling.

KFF Health News

September 17, 2025

‘Death by a Thousand Cuts’

Rural South Texas hospitals and physicians face mounting strain as rising uninsured rates and federal funding cuts threaten access to essential health care.

KFF Health News

December 11, 2024

ALS Drug Misses Trial Goals

A mid-stage trial for an experimental drug in ALS patients did not meet its main goal, with patients showing more gastrointestinal upset compared to a placebo, and differing death rates between groups. Results will be presented next year, and a long-term extension study will continue.

Reuters

April 29, 2024

Exposed to Agent Orange at US Bases, Veterans Face Cancer Without VA Compensation

A veteran's struggle for recognition of health issues linked to exposure to a controversial herbicide used by the military.

KFF Health News

April 14, 2025

Inebilizumab Effective for Myasthenia Gravis

CD19+ B-cell-depleting therapy shows significant improvement in function and disease severity in phase III trial of autoimmune neuromuscular disorder.

Conexiant